PicoCELA Inc. (NASDAQ:PCLA) Sees Significant Decline in Short Interest

PicoCELA Inc. (NASDAQ:PCLA) was the recipient of a large decrease in short interest in December. As of December 15th, there was short interest totaling 12,084 shares, a decrease of 89.5% from the November 30th total of 114,853 shares. Based on an average daily trading volume, of 130,843 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the shares of the company are sold short. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 130,843 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Investors Weigh In On PicoCELA

A hedge fund recently bought a new stake in PicoCELA stock. XTX Topco Ltd bought a new stake in PicoCELA Inc. (NASDAQ:PCLA) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm bought 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA as of its most recent SEC filing.

PicoCELA Trading Up 79.4%

NASDAQ PCLA traded up $0.18 during midday trading on Friday, hitting $0.42. The company had a trading volume of 333,612,682 shares, compared to its average volume of 5,806,538. The firm has a 50-day moving average price of $0.31 and a 200-day moving average price of $0.65. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.19 and a quick ratio of 1.74. PicoCELA has a twelve month low of $0.12 and a twelve month high of $9.80.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a research report on Tuesday, October 14th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.